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Abstract
Background: Deregulation of hypothalamic fatty acid sensing lead to hepatic insulin-resistance which may partly contribute
to further impairment of glucose homeostasis.
Methodology: We investigated here whether hypothalamic nitric oxide (NO) could mediate deleterious peripheral effect of
central lipid overload. Thus we infused rats for 24 hours into carotid artery towards brain, either with heparinized
triglyceride emulsion (Intralipid, IL) or heparinized saline (control rats).
Principal Findings: Lipids infusion led to hepatic insulin-resistance partly related to a decreased parasympathetic activity in
the liver assessed by an increased acetylcholinesterase activity. Hypothalamic nitric oxide synthases (NOS) activities were
significantly increased in IL rats, as the catalytically active neuronal NOS (nNOS) dimers compared to controls. This was
related to a decrease in expression of protein inhibitor of nNOS (PIN). Effect of IL infusion on deregulated hepatic insulin-
sensitivity was reversed by carotid injection of non selective NOS inhibitor NG-monomethyl-L-arginine (L-NMMA) and also
by a selective inhibitor of the nNOS isoform, 7-Nitro-Indazole (7-Ni). In addition, NO donor injection (L-arginine and SNP)
within carotid in control rats mimicked lipid effects onto impaired hepatic insulin sensitivity. In parallel we showed that
cultured VMH neurons produce NO in response to fatty acid (oleic acid).
Conclusions/Significance: We conclude that cerebral fatty acid overload induces an enhancement of nNOS activity within
hypothalamus which is, at least in part, responsible fatty acid increased hepatic glucose production.
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Introduction
Metabolic Syndrome is a constellation of disturbance where
insulin resistance is considered as a key factor in the onset of
disorders [1]. In the early stage, and before any change in fat mass
and/or ectopic storage of triglycerides (TG) within liver or muscle,
changes in autonomic nervous system (ANS) activity could modify
both insulin secretion and action [2–4]. In central nervous system
(CNS), hypothalamus is a key regulator of ANS output as well as a
nutrient sensor. Indeed, growing evidences show involvement of
both glucose [5–7] and fatty acids (FA) [8,9] sensitive neurons
within hypothalamus, especially arcuate and ventromedial part, in
the regulation of both energy homeostasis and food intake [10–
12]. It has been shown that short term intracerebroventricular
infusion of oleic acid reduced both food intake and hepatic glucose
production [13]. Besides this acute effect of hypothalamic FA
sensing, it appeared that central FA overload -which could occur
during metabolic diseases- deregulate such sensing, thus leading to
impaired CNS control of glucose homeostasis, insulin secretion
and sensitivity [14]. This deregulation of sensing may impair CNS
control of hepatic glucose output through dysfunction of
autonomic balance and hypothalamic ANS output [15,16].
However, the molecular events involved in effects of high FA
exposure in the hypothalamus are still poorly understood. In the
present study, we hypothesized that the hypothalamic nitric oxide
(NO) production mediates the central effects of FA. Indeed it has
been shown in other tissues such as pancreatic beta cell that lipids
exposure activates NO pathway in physiological and physiopath-
ological conditions [17,18]. NO is generated from L-Arginine
amino acid by NO synthase (NOS), a process that occurs in most
tissues including brain [19]. There are 3 different isoforms of NOS
which can be divided in two categories: constitutive, Ca
2+
dependent NOS (endothelial or eNOS, and neuronal or nNOS),
and inducible NOS (iNOS), Ca
2+ independent. Constitutive NOS
mediates cell signaling, whereas iNOS activation occurs during
inflammation, and leads to cytotoxic effects. Since iNOS produces
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6649larger amount of NO than constitutive NOS [20], NO generation
by the latter appears to be more adapted in cell signaling. nNOS
activity is partly regulated by PIN (protein inhibitor of neuronal
NOS), which has been identified in rat brain [21]. Binding of PIN
prevents homodimerization of nNOS with as a result an inhibition
of NO production (14). Recently NO has been identified as a
regulator of nutrient metabolism [22] and its production is
modulated by dietary factors [23]. NO is also a modulator of
electrical activity of hypothalamic neurons involved in the control
of energy homeostasis [24,25].
We hypothesized that central lipid overload may induce NO
production within the hypothalamus which in turn may lead to
impairment of insulin secretion and action through changes in
autonomic nervous system output.
Results
Oleic acid stimulates NO production in rat ventromedial
hypothalamic (VMH) neurons (Figure 1)
DAF-FM loaded VMH cultured neurons were visualized
under brightfield and fluorescent (FITC) microscopy (Figure 1A,
1B). DAF-FM fluorescence intensity increased when NO was
produced. Figure 1C shows an example of a group of neurons
where one of them increased its DAF-FM fluorescence intensity
above 5% and eight of them did not increase their DAF-FM
intensity in response to 2 mM oleic acid. Overall, oleic acid
increased DAF-FM fluorescence intensity in 15.161.53% of
VMH cultured neurons (n=386; Figure 1D). Non selective NOS
inhibitor L-NMMA significantly decreased the DAF-FM inten-
sity in response to oleic acid to 3.2361.4% (n=251; Figure 1D).
We conclude that some VMH neurons respond to fatty acid by
producing NO.
Plasma parameters and food intake following
intracarotid IL infusion (Table 1)
Neither plasma insulin nor glucose concentrations were modified
in IL rats compared with C rats at the end of the 24 h lipid infusion.
Plasma FA concentration is not modified by lipid/heparin infusion
(Time courseC vs.IL:0 h:419.1643.4 mMvs.419657,1 mM;4h
: 543.3671.5 mM vs. 542.6650.1 mM ; 8 h : 559.1657.2 mMv s .
544.6650.2 mM; 20 h: 504.3645.6 mM vs. 528.5622.4 mM; 24 h:
523.6680.5 mM vs. 499.363.5 mM). Plasma corticosterone con-
Figure 1. NO production by VMH neurons in response to oleic acid. A and B: Bright field (A) and DAF-FM fluorescence intensity images of
cultured (24 H) VMH neurons from rats. Cells (solid arrow) are plated with fluorescent beads (broken arrow) which are used to calibrate changes in
cell fluorescence intensity. C: Example of VMH neurons which increase (solid line, 1 neuron) or do not change (dashed line, 8 neurons) their DAF-FM
fluorescence intensity in response to oleic acid (2 mM). Neurons increasing their DAF-FM fluorescence intensity above 5% after 15–25 min post oleic
acid addition are considered to produce NO in response to oleic acid. D: Percentage of VMH neurons that increased their DAF-FM fluorescence
intensity [NO production] in response to oleic acid (2 mM) in the presence or absence (Control) of the non-selective NOS inhibitor N-Methyl-L-arginine
(L-NMMA, 1 mM). Data are presented as mean6sem. *: p,0.05. Total number of cells – number of dishes used are given on the top of each bar.
doi:10.1371/journal.pone.0006649.g001
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ACTH concentration was unchanged. IL/heparin infusion had no
effect on body weight or food intake (Table 1).
Intracarotid IL infusion increases hypothalamic NOS
activities (Figure 2)
In the IL group, the activity of total NOS and constitutive
(nNOS/eNOS) was increased in mediobasal hypothalamus
(respectively by 81% and 84%) compared to C rats. Moreover
cortical NOS activity was not modified by infusion (Figure 2A).
Carotid injection of L-NMMA (non selective NOS inhibitor)
normalized NOS activities in IL rats without any change in C rats.
L-Arginine administration stimulated constitutive NOS activity in
C rats at the enzyme activity reached the same level as in the IL
group (Figure 2B). iNOS activity was significantly increased in IL
hypothalamus, but not in cortex (Figure 2A/B).
Systolic blood pressure measurement reveal that lipid infusion
or L-NMMA injection into carotid catheter, in C rats as well as in
IL rats, did not lead to significant changes in vascular tone and
heart beat, compared to a control saline injection. (data not shown)
Effect of intracarotid IL infusion on liver parameters in
basal state (Figure 3)
Liver TG content (Figure 3A) and PEPCK activity (Figure 3B)
are not modified in IL rats, whereas the hepatic glycogen content
was significantly reduced in IL rats (Figure 3C). IL rats liver
Table 1. Basal characteristics of the experimental groups
after 24 h of carotid infusion.
CI L
Body weight (g) 236.767.7 235.169.7
Food intake (g/Kg bw) 79.8564.3 73.465
Plasma TG (mg/ml) 0.8160.09 0.7560.09
Glycemia (mmol/l) 6.660.15 6.5560.14
Insulinemia (pmol/l) 288636.3 246.5620.7
Corticosteronemia (ng/ml) 416638.6 252.9643.9*
Plasma ACTH (pg/ml) 265638 207.1628.4
C, control rats infused with saline/heparin for 24 h through the carotid artery; IL,
rats infused with Intralipid/heparin for 24 h through the carotid artery. Values
are means6SEM in each group.
*p,0.05 compared to C rats.
doi:10.1371/journal.pone.0006649.t001
Figure 2. Effect of lipid infusion on central NOS activities. A: Hypothalamic and cortical NOS activities after 24 h of Intralipid/heparin infusion
(IL 24 h) or saline/heparin infusion control group (C). Results are expressed as c.p.m per mg of tissue. B: Hypothalamic NOS activities of IL and C rats
treated or not with acute injection of non selective NOS inhibitor, L-NMMA. The last right bar displays NOS activities in C rats injected with NOS
substrate, L-Arginine. Results are expressed as percentage of C group activities. * p,0.05 vs. C.
doi:10.1371/journal.pone.0006649.g002
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(Fig. 3D).
Central NOS inhibitors and NO donors regulate glucose-
induced insulin secretion (Figure 4)
The time course of glycemia following glucose loading was
similar in control rats and IL rats, independently to carotid
injection of non selective NOS inhibitor L-NMMA (Figure 4A). In
contrast, glucose-induced insulin secretion (GIIS) was greater in IL
rats than in C rats (time-course of insulinemia (Figure 4A) and
insulinogenic index, DI/DG, Figure 4B). L-NMMA injection
reversed this hypersecretion of insulin showed in IL rats whereas it
had no significant effect on GIIS in control rats (Figure 4A/B).
Selective nNOS inhibitor 7-Ni treatment through carotid artery
also normalized DI/DG in IL rats (Figure 4C). In contrast
injection of W1400 (selective iNOS inhibitor) did not reversed
increased GIIS in IL rats (Figure 4D). Treatments with L-Arginine
(NOS substrate) and SNP (chemical NO donor) significantly
increased DI/DG in C rats, to reach a value similar to that of IL
rats (Figures 4E and 4F), mainly through an increase in insulin
plasma concentration.
Central NOS inhibitors and NO donor effects on glucose
turnover rate (Figures 5)
Glucose turnover rate (GTR) was measured in basal and under
hyperinsulinemic-euglycemic clamp conditions. In basal state
GTR was similar in both groups (,10 mg/min/Kg, not shown).
During hyperinsulinemic-euglycemic clamp procedure, plasma
insulin concentrations were increased to a similar extent (,3.5-
fold above basal values) in all groups. Glucose infusion rate (GIR)
at the steady-state was significantly lower in IL rats (14.561.1 vs.
21.8361.5, p,0.01) whereas increase in glucose utilization was
similar in C and IL rats (Figure 5A). In contrast hepatic glucose
production (HGP) remained significantly higher (p,0.01) in IL
rats than C rats, highlighting hepatic insulin resistance (Figure 5A).
Carotid injections of L-NMMA had no effect on HGP in C rats
but strongly decreased hepatic glucose output in IL rats, thus
normalizing hepatic insulin sensitivity (Figure 5A). As selective
iNOS inhibitor (W1400) had no effect on GIIS, the drug was not
tested in the clamp study. Regarding effect of nNOS selective
inhibitor (7-Ni), HGP was normalized in IL rats (Figure 5B). This
suggests that inhibition of nNOS is sufficient to counteract effect of
IL infusion on glucose homeostasis.
The carotid injection of NOS substrate, L-Arginine, as well as
SNP (chemical NO donor) led to an increase in HGP in C rat
which reflected the induction of hepatic insulin resistance
(Figure 5C and 5D).
Liver parameters during clamp procedure (Figure 6)
As shown in Figure 6A, at the end of the clamp procedure, the
glycogen content was markedly reduced in IL rats compared to C
rats, and both values were similar to those measured in basal
condition (see Figure 3C). Carotid injection of L-NMMA (non
selective NOS inhibitor) partially restored glycogen content of IL
rats, whereas no significant changes were seen in C rats. L-NMMA
injection led to a 2-fold increase in G-6-P content in both IL and C
rats (Figure 6B). Liver PEPCK activity was more elevated in IL
rats, thus reflecting increased gluconeogenesis, and L-NMMA
injection did not affect it (Figure 6C).
Figure 3. Hepatic parameters after 24 h of infusion in C rats (NaCl/heparin) and in IL rats (IL/hep). A: liver triglycerides content, B: liver
PEPCK activity, C: liver glycogen, D: liver acetylcholinesterase activity. Values are means6SEM in each group. * p,0.05 vs. controls.
doi:10.1371/journal.pone.0006649.g003
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by IL infusion (Figure 7)
The mRNA levels of the three NOS in the hypothalamus of IL
rats did not differ from controls (Figure 7A). However, as shown in
Figures 7B and 7C, 24 h of lipid/heparin infusion led to a marked
increase in the dimer/monomer ratio of the nNOS isoform, which
could explain the increased activities we measured. In addition,
PIN mRNA level appeared unchanged (Figure 7A), whereas the
PIN protein showed a tendency to decrease in IL rats (9.662.2 vs
12.3263 in C rats, NS). No significant change in gene expression
were observed for the inflammatory cytokines (Figure 7A), known
to be involved in iNOS induction [20]. Likewise, oxidative stress
enzymes, which could interfere with NO metabolism, remained
unchanged with the following two exceptions. The expression of
isocitrate dehydrogenase and glutathione reductase, enzymes
known to be inactivated by NO [26,27], were significantly
down-regulated in the mediobasal hypothalamus of IL rats
(Figure 7A). Moreover IL rats displayed a 45% decrease in
glutathione reductase enzymatic activity in the hypothalamus,
compared to controls (data not shown).
Discussion
In this study we showed that central lipid overload led to increased
hypothalamic NOS activity and consequently to both hepatic insulin
resistance and increased GIIS. Effects of lipid overload were mimicked
in normal rats centrally receiving NO donors and selective inhibition of
hypothalamic nNOS activity was sufficient to block such effects.
First of all, we demonstrated that central lipid overload
increased hypothalamic NOS activities. We cannot totally exclude
an extra-hypothalamic effect; however we reported here that no
change in NOS activities was observed in cortex of IL infused rats
compared to controls. In addition, the structure and function of
blood brain barrier (BBB) within hypothalamus -especially median
eminence- is quite different from other part of the brain (review in
[28]) and Norsted et al recently evidenced that in medio-basal
hypothalamus the structure of the endothelium is not composed by
the same proportion of occludins and tight junctions suggesting an
increased permeability to circulating substances [29]. Finally, it
has been demonstrated that palmitate uptake in hypothalamus is
about 10 to 15% versus less than 2% in other brain areas [30].
Taken together, these data suggest a local effect of lipids close to
their route of infusion.
As a basis for the in vivo study, we demonstrated that oleic acid
stimulated NOS-dependent NO production in cultured VMH
neurons (a nucleus in which NOS-immunostaining has been also
described [31] and known to be involved in the regulation of both
energy homeostasis and autonomic nerves output). It does not rule
out that glial/endothelial cells may also play a role in vivo [32],
and we cannot exclude that NO production may also occur in
other hypothalamic nuclei. Indeed we previously reported that c-
fos immunostaining, a marker of neuronal activation, was induced
in arcuate nucleus as well as paraventricular nucleus in response to
IL infusion [14]. It must be pointed out that c-fos immunostaining
was not changed in other part of the brain in IL vs. control rats
[14].
Figure 4. Assessment of glucose induced insulin secretion. Time course of plasma glucose and insulin (A) concentrations in response to
glucose load in C rats (open squares), C+L-NMMA rats (open triangles, dotted line), IL rats (filled squares) and IL+L-NMMA rats (filled triangles, dotted
line). B, C, D, E, F: insulinogenic index (DI/DG), i.e. the area under curve of insulinemia time course divided by the area under curve of glycemia time
course, after carotid injections of respectively with L-NMMA, 7-Ni, W1400, L-Arginine and SNP. Drugs or saline are injected 5 minutes before glucose
loading into saphenous vein. Values are means6SEM in each group. * p,0.01 vs C rats. L-NMMA: non selective NOS inhibitor. 7-Ni: selective neuronal
NOS inhibitor. W1400: selective inflammatory NOS inhibitor. SNP: chemical NO donor. IL 24 h: rats infused with of Intralipid/heparin through the
carotid artery towards the brain for 24 h. C: rats infused for 24 h with saline/heparin.
doi:10.1371/journal.pone.0006649.g004
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hypothalamic NOS activity and this is mainly due to constitutive
NOS isoforms activation. While an increase in the three NOS
isoformsactivitiesoccurred,iNOSactivationwasprobablynotakey
actor. First, increased iNOS activity was modest, as depicted in
figure 2, compared to constitutive NOS. In addition, this was not
associated with increased mRNA expression of enzyme and
inflammatory cytokines, as classically observed in iNOS pathway
activation [20]. Finally, to further identify which NOS isoform was
responsible for IL effects, pharmacological studies were performed
and pretreatment with a selective iNOS inhibitor (W1400) did not
prevent lipid effects on GIIS. Taken together, iNOS activity
implication in IL effects is probably modest compared to
constitutive NOS. However, pretreatment with L-NMMA, a non
selective NOS inhibitor, prevented lipids effects. To further
determine which isoform was mainly involved we made additional
studies with selective NOS inhibitors and we observed that
pretreatment with the nNOS selective inhibitor, 7-Ni, was sufficient
to normalize insulin secretion and action in liver, suggesting a key
role for this isoform in mediating lipid effects. However, since
activity assay does not discriminate between eNOS and nNOS, we
cannot totally exclude that increased eNOS activity –if it occurred-
could be also partly responsible for IL effect.
Some hypothesis can be made to elucidate the way of action of
NO. From our in vitro study, it appears that a rapid NO production
could also imply a rapid action on neuronal membrane potential.
It has been reported in isolated islets of Langerhans that NO may
act through GPR40 by modulating intracellular calcium concen-
tration [33]. In addition, several studies suggested that NMDA-
evoked intracellular [Ca
2+] transients were modulated by
endogenous NO production, which lead to release of calcium
from the mitochondrial pool [34], or that NO synthesis was
important for the proaversive effects produced by activation of
glutamate-NMDA receptors located within limbic midbrain
structure [35]. Thus effect of NO could involve change in channel
activities and consequently modulation of neuronal activities.
Besides this effect of NO, we previously reported that fatty acid
metabolism was important to modulate their effects [14]
suggesting involvement of several pathways.
Our data also showed that lipid-induced nNOS activity could
be related to the increase of nNOS dimer to monomer ratio,
probably ensue from the diminution of PIN expression, although
non significant. Indeed, this could account for the increased NO
production [36]. This modulation of nNOS catalytic activity is
assume to prevent deleterious NO overproduction as reported in a
study where PIN expression was increased [37]. In addition, acute
injection in control rats with either NOS substrate L-arginine, or
chemical NO donor, SNP, led to hepatic insulin resistance and
increased GIIS, strengthening the idea that enhanced hypotha-
lamic NO production was an essential step in the onset of these
metabolic dysfunctions.
Activity and mRNA expression of glutathione reductase, a
potent anti-oxidant enzyme, was also decreased in the hypothal-
amus of IL rats. This could also contribute to an increase in
cellular NO availability independently of an action on NOS
activity [38]. Taking these data together, we can devise that a
context of lipid excess may lead to both enhancement of
hypothalamic NOS activity and NO availability.
Figure 5. Glucose turnover rate during euglycemic-hyperinsulinemic clamps. Glucose Utilization and Hepatic Glucose Production during
euglycemic-hyperinsulinemic clamp (0.4 U?kg
21?h
21) in Control and IL rats before and after L-NMMA (A), 7-Ni (B). L-Arginine (C) or SNP (E) carotid
injection. L-NMMA: non selective NOS inhibitor. 7-Ni: selective neuronal NOS inhibitor. W1400: selective inflammatory NOS inhibitor. SNP: chemical
NO donor. Values are means6SEM in each group. * p,0.01 vs C rats.
doi:10.1371/journal.pone.0006649.g005
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carotid lipid infusion led to hepatic insulin resistance. This is
consistent with previously described effects, demonstrating that
high levels of lipid exposure in the hypothalamus may partly
contribute to the etiology of type 2 diabetes [39,40]. In our model
this hepatic insulin-resistance was not related to ectopic storage of
TG within liver. Thus a major impact of carotid IL infusion could
be related to change in the ANS output, especially parasympa-
thetic component. Indeed, as attested in this study, IL rats
displayed a 2-fold increase in liver acetylcholinesterase activity,
which is likely to promote increased breakdown of acetylcholine
and reduced activity at the muscarinic receptor level [41]. Since
the parasympathetic nervous system stimulates glycogen synthase
activity [42], a lower parasympathetic function within the liver
could partly explain the decreased glycogen content - hallmark of
liver insulin resistance [43,44]- observed in our IL rats. This has
been demonstrated in a model of rats with specific liver vagotomy,
which display significant impairment in liver glycogen storage and
impaired hepatic sensitivity to insulin [45]. Thus, even if we did
not evidenced a clear cause-effect relationship, we can conclude
from our data, that there is a correlation between increased
cholinesterase activity and decreased hepatic glycogen content. In
addition, it has been reported that NO modulates pre-autonomic
neurons activity in the paraventricular nucleus of the hypothal-
amus, a key regulator of ANS output [46,47]. Finally we could also
hypothesize that increased insulin secretion in response to central
IL infusion could, at least in part, be responsible for increased
hepatic insulin resistance.
As mentioned above, both L-NMMA and 7-Ni treatments
prevented the deleterious effects of central lipid overload on
hepatic insulin sensitivity. Regarding the activity of the gluconeo-
genic enzyme PEPCK, elevated in IL rats during EG-HI clamps,
L-NMMA had no effect on it. This suggests that hepatic effects of
central NOS enhancement mainly involve a control of liver
glycogenolysis. Moreover, central L-NMMA injection increased
liver glucose-6-phosphate content in both groups, indicating a
better insulin sensitivity [43]. Together, with the unchanged
PEPCK activity, this suggests that the main point of control is
depending on a decreased flux of substrate through glucose-6-
phosphatase. In addition, there is only hepatic insulin resistance
whereas insulin stimulated glucose uptake remained similar in
both groups. Furthermore, increased GIIS in IL rats suggests an
adaptation to insulin-resistance.
In conclusion, we demonstrated here that impairment of hepatic
insulin action in response to lipid overload within hypothalamus is
related to increased NOS activity, mainly involving nNOS.
Deregulation of hypothalamic lipid sensing and NO signaling
pathway is involved in the setting of hepatic insulin resistance,
Figure 6. Hepatic parameters during euglycemic-hyperinsulinemic clamp procedure. A: Glycogen content, B: Glucose-6-Phosphate
content, C: PEPCK activity in the liver of control and IL rats (injected or not with non selective NOS inhibitor, L-NMMA) at the end of the clamp
procedure. Values are means6SEM in each group. * p,0.01 vs. C rats; 1 p,0.01 vs. IL rats.
doi:10.1371/journal.pone.0006649.g006
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could take an active part in the early dysfunctions leading to type 2
diabetes in predisposed subjects.
Materials and Methods
Animals and experimental design
The experimental protocol was approved by the institutional
Animal Care and Use Committee of the University of Paris 7.
Male Wistar rats, two-month-old, 250–275 g, (Charles River,
l’Arbresle, France) were housed individually in stainless steel cages
in a room maintained at 2463uC with lights on from 7 am to 7 pm
hours. Food (regular chow diet: proteins 19.4%; carbohydrates
59.5%; lipids 4.6%; vitamins and minerals 16.5%, Usine
d’Alimentation Rationnelle, Rabalot, France) and water was
provided ad libitum.
Carotid lipid infusions
The unrestrained infusion technique was used, as previously
described [48]. Briefly, before the beginning of the infusion, rats
were anaesthetized with pentobarbital (50 mg/Kg i.p.; Sanofi,
Libourne, France) for catheterization of right carotid artery,
towards the brain. Catheter was then exteriorized at the vertex of
the head, and animals were allowed to recover for 5 days. Then
catheter is connected to a swiveling infusion device, allowing the
animal free access to water and food. Rats were infused with a
triglyceride emulsion (Intralipid 20%; KabeVitrum, Stockholm,
Sweden) heparinized (20 U/mL) (IL rats), whereas control rats (C
rats) were infused with saline/heparin, at 2 mL/min on 24 hours.
Heparin was added to the lipid emulsion in order to stimulate
lipoprotein lipase activity. Arteriovenous blood was collected from
caudal vessels (,80 mL) for measurement of plasma FA, glucose
and hormones concentrations.
Measurement of NO production in VMH cultured
neurons using 4-amino-5-methylamino-29,79-
difluorofluorescein (DAF-FM)
The experimental protocol was approved by the institutional
Animal Care and Use Committee of the University of Medicine
and Dentistry of New Jersey. 3–4 weeks old male rats were used in
order to prepare VMH dissociated cultured neurons as previously
described [24,25]. Twelve hours after, neurons were incubated
with 1 mM DAF-FM at 37uC with extracellular fluid (ECF)
containing 2.5 mM of glucose for 30–45 min. DAF-FM is then
removed from the cells, and neurons were visualized on an
Olympus BX61 WI microscope with a 10X objective for
measurement of DAF-FM intensity fluorescence (green filter,
excitation 488 nm, emission 515–530 nm). Images are captured
(Photometrics, Cool Snap HQ CCD camera) every minutes for
30 min and acquired/analyzed with MetaMorph software (Uni-
versal Imaging Corporation). The fluorescence intensity was
expressed as gray scale units/pixel. Data were normalized
according to the intensity of the fluorescent bead standards coated
with the cells on the coverslips. Control images were taken for 5
Figure 7. Hypothalamic gene expression after 24 h IL infusion. A: mRNA expression of NO pathway proteins, inflammatory cytokines and
oxidative stress enzymes in the hypothalamus of C rats and IL rats. Values are means6SEM in each group (arbitrary units). B: Western blot of nNOS
monomers and dimers in C and IL rats, and D: expression of the ratio dimers/monomers (D/M) after image analysis (quantification of the intensity of
the blots). Values are means6SEM in each group. * p,0.01 vs C rats.
doi:10.1371/journal.pone.0006649.g007
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media. At this concentration oleic acid is water soluble. Then the
percent change of DAF-FM fluorescence intensity for each neuron
was calculated from the control images. As previously showed,
neurons increasing their DAF-FM fluorescence intensity above 5%
were considered as NO producing cells.
Food intake
Daily food intake was measured at 9 am. Food intake is reported
to body weight of animals and expressed in gram of food per kilo
of body weight.
Liver analysis: TG, glycogen and glucose 6-phosphate (G-
6-P) contents, acetylcholinesterase activity
All livers were sampled using the freeze-clamp procedure. The
liver TG content was measured with an assay based on glycerol
detection [49]. Briefly, 0.1 g of frozen liver tissue was minced in
2m lo f4 uC ethanol. Cell debris was allowed to settle, and further
clarification was achieved by centrifugation of the supernatant at
15,000 g for 10 min at room temperature [50]. 10 mL of the
supernatant were used to dose TG concentration using the serum
Triglyceride Determination kit (Sigma, St. Louis, MO). Liver
glycogen and glucose-6-phosphate content were determined
according to previously described enzymatic assay procedures
[51] [52]. PEPCK activity was assayed in the supernatant of liver
homogenates according to the procedure described [53]. Deter-
mination of liver acetylcholinesterase activity (AmplexH Red
Acetylcholine/Acetylcholinesterase Assay Kit, Molecular Probes,
Paisley, UK), was performed to evaluate parasympathetic nervous
system function.
Measurement of hypothalamic NOS activities
At the end of infusion periods, rats underwent an acute
carotid injection of non-isoform specific NOS inhibitor, NG-
monomethyl-L-arginine (L-NMMA, 0.5 mg/Kg of rat body
weight), L-Arginine (100 mg/Kg) or saline. 10 minutes later,
mediobasal part of hypothalamus (ie VMH+ARC, as described
[54]) were collected, weighted (10 min delay was sufficient to
cause significant functional effects, as attested by the IVGTT
study) and homogenized in buffer (250 mM Tris-HCl, 10 mM
EDTA and EGTA). NOS activity assay kit (Calbiochem,
Darmstadt, Germany) based on the stoichiometric biochemical
conversion of L-Arginine into L-Citrulline by NOS. Briefly
tissues were incubated with radiolabelled [
3H]-L-Arginine
(1 mCi/mL )i nac o l u m nw i t har e s i nw h i c hb i n d sL - A r g i n i n e
but not L-Citrulline, and we quantified [
3H]-L-Citrulline
radioactivity in the filtrate. To distinguish the constitutive
NOS activity from iNOS activity, we omitted calcium chloride
in the assay medium of the iNOS group. Results are given in
CPM by mg of tissue.
Carotid injections of pharmacologic NO pathway
modulators
Prior to glucose tolerance test or during the euglycemic-
hyperinsulinemic clamp, rats underwent an acute injection of L-
NMMA into carotid catheter used for lipid infusion. L-NMMA
(0.5 mg/kg of rat body weight), specific inhibitor of neuronal
NOS, 7-Nitro-indazole (7-Ni, 0.5 mg/kg), specific inhibitor of
inducible NOS, W1400 (0.05 mg/kg), L-Arginine, as the substrate
of NOS (100 mg/kg) and Sodium Nitro-Prusside, SNP (0.5 mg/
kg), as pharmacological NO donor (Sigma-Aldrich, L’Isle
d’Abeau, France) was injected during 1 minute. Control injections
were made with NaCl 0.9%.
Glucose-induced insulin secretion test
Insulin secretion in response to glucose was studied in C and IL
rats, with or without the injection of NO pathway modulators, 5
minutes before glucose injection. Food was removed 5 h before
glucose injection into the saphenous vein (0.5 g/kg body weight) of
anaesthetized rats. Blood samples were drawn from caudal vessels
at 0, 1, 3, 5, 10, 15, 20 and 30 min following glucose injection.
Glycemia was immediately measured using a glucose analyzer
(Roche Diagnostics, Meylan, France). Plasma was then removed
and stored at 220uC until radioimmunoassay of insulin.
Measurement of glucose turnover rate during
hyperinsulinemic-euglycemic clamp
After infusion, glucose turnover rate (GTR), ie both glucose
disposal rate (GDR) and hepatic glucose production (HGP), was
measured under hyperinsulinemic-euglycemic clamp conditions,
in both IL rats and C rats before and after NO pathway
modulators injection. Clamp was performed in 5 h food-deprived
and anaesthetized rats. We previously reported that GTR values
were similar in awake [55,56] and anaesthetized rats [14,57].
Blood sampling was performed with right jugular vein catheter.
Basal blood glucose and plasma insulin were measured before
insulin infusion. Then a priming dose of insulin (20 mU; Actrapid,
Novo, Copenhagen, Denmark) and [
3H]-3-glucose (4 mCi) was
injected. After insulin (0.4 U.kg
21.h
21) and radiolabelled glucose
(0.2 mCi/min) was continuously infused in sapheneous vein at a
constant rate of 20 mL/min throughout the clamp study. During
the procedure, blood was sampled from caudal vessels every
15 min to determine blood glucose and to adjust the rate of
unlabelled glucose infusion to maintain euglycemia. The steady-
state was attained within 30–40 min and maintained for 40 min
thereafter. Blood samples were drawn during the steady-state
euglycemic clamp for glucose disposal rate evaluation (t<60, 70
and 80 min), before any injection of NO pathway modulator.
After the carotid injection of L-NMMA, 7-Ni, Arginine and SNP,
another set of blood was sampled when a new steady-state has
been reached (t<120 min after the beginning of the procedure).
For the assay of [
3H]-3-glucose, blood samples were deprotein-
ized (Ba(OH)2 and ZnSO4) and the supernatant evaporated to
remove tritiated water. Dry residue was dissolved in 0.5 ml water
and 9 ml scintillation solution was added (Aqualuma plus, Lumac,
The Netherlands). Radioactivity was determined in a Packard Tri-
Carb 460C liquid scintillation system.
Calculations of glucose kinetics
In the basal steady state, the rate of glucose appearance (Ra,
reflecting HGP) is equal to the glucose disposal rate (Rd, reflecting
glucose utilization rate, GUR). During the euglycemic-hyperinsu-
linemic clamp, at steady state, Rd=Ra+Ra’ (where Ra’, GIR). Rd
was calculated according to Rd=Ra=[
3H]-3-glucose infusion
rate (in disintegrations/minute) divided by blood glucose specific
activity (in disintegrations/minute per milligram), Ra was obtained
according to Ra=Rd2Ra’, i.e. GUR-GIR.
Hypothalamic nNOS and PIN protein expression
Mediobasal hypothalami were homogenized in 20 mmol/l Tris
lysis buffer pH 7.4, and protease inhibitors (Roche Applied
Science, Mannheim, Germany). Then, 50 mg soluble proteins
were separated on a 7.5% SDS-polyacrylamide gel for nNOS
detection and on a 14% tricine-polyacrylamide gel for PIN
detection. Protein expressions were detected by Western Blot
analysis. Monoclonal anti-nNOS and anti-PIN antibodies (Trans-
duction Laboratories, Lexington, KY) were diluted at respectively
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chemiluminescence reaction (Amersham Biosciences, Little Chal-
font, U.K) after incubation with a horseradish peroxidase-
conjugated anti-mouse antibody (diluted 1:3000, Sigma-Aldrich,
Steinheim, Germany).
Measurement of gene expression
Total RNA were isolated from hypothalamus using RNeasy
Lipid mini kit (Qiagen, Courtaboeuf, France).Real time quantita-
tive PCR amplification reaction were carried out in a LightCycler
1.5 detection system (Roche, Meylan, France) using the Light-
Cycler FastStart DNA Master plus SYBR Green I kit (Roche).
The mRNA transcript level for each gene was normalized against
housekeeping gene cyclophilin B because we previously checked
that this gene expression was not modified by lipid infusion.
Systolic blood pressure measurement
To assess a potential effect of the 24 h lipid infusion on whole-
body vascular tone, as well as a potential effect of carotid NOS
inhibitor injection, we measured heart rate, systolic and diastolic
blood pressure on both conscious IL and C rats before and after L-
NMMA injection, using a computerized tail-cuff method (BP-
2000, Visitech Systems, Apex, NC) [58]. Briefly animals were
maintained restrained at 37uC in the dark and tail cuffs were
placed on the tail of each of the rats. Animals were acclimatized
with 10 preliminary measurements and the final systolic blood
pressure and heart beat values were calculated as the average of 20
measurements.
Analytical methods
Blood glucose was determined using a glucose analyzer (Accu-
Chek, Roche, Mannheim, Germany). Plasma insulin concentra-
tion, as well as plasma corticosterone and ACTH levels, were
determined by radioimmunoassay (DiaSorin, Les Ullis, France).
FFA concentrations were measured using an enzymatic assay
(NEFA-C test; Wako, Germany).
Statistical analysis
Data are expressed as means6SEM. Data were analyzed using
Stat View 5.0 for Windows (SAS Institute, Cary, NC) for statistical
significance by applying respectively a Student t-test, a Mann-
Whitney test or a two-way ANOVA test for repeated measure-
ments, when appropriate. A p value of less than 0.05 was
considered statistically significant.
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